Cargando…

Investigating natural compounds against oncogenic RET tyrosine kinase using pharmacoinformatic approaches for cancer therapeutics

Rearranged during transfection (RET) tyrosine kinase is a transmembrane receptor tyrosine kinase regulating vital aspects of cellular proliferation, differentiation, and survival. An outstanding challenge in designing protein kinase inhibitors is due to the development of drug resistance. The “gain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parate, Shraddha, Kumar, Vikas, Chan Hong, Jong, Lee, Keun Woo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Royal Society of Chemistry 2022
Materias:	Chemistry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978841/ https://www.ncbi.nlm.nih.gov/pubmed/35425116 http://dx.doi.org/10.1039/d1ra07328a

Ejemplares similares

Identification of CDK7 Inhibitors from Natural Sources Using Pharmacoinformatics and Molecular Dynamics Simulations
por: Kumar, Vikas, et al.
Publicado: (2021)

Investigation of Marine-Derived Natural Products as Raf Kinase Inhibitory Protein (RKIP)-Binding Ligands
por: Parate, Shraddha, et al.
Publicado: (2021)

Identification of Activated Cdc42-Associated Kinase Inhibitors as Potential Anticancer Agents Using Pharmacoinformatic Approaches
por: Kumar, Vikas, et al.
Publicado: (2023)

Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics
por: Parate, Shraddha, et al.
Publicado: (2021)

Identification of Flavonoids as Putative ROS-1 Kinase Inhibitors Using Pharmacophore Modeling for NSCLC Therapeutics
por: Parate, Shraddha, et al.
Publicado: (2021)

Computational Investigation Identified Potential Chemical Scaffolds for Heparanase as Anticancer Therapeutics
por: Parate, Shraddha, et al.
Publicado: (2021)

Computational Simulations Identified Marine-Derived Natural Bioactive Compounds as Replication Inhibitors of SARS-CoV-2
por: Kumar, Vikas, et al.
Publicado: (2021)

3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Dynamics Simulations for the Identification of Spleen Tyrosine Kinase Inhibitors
por: Kumar, Vikas, et al.
Publicado: (2022)

Pharmacoinformatic Investigation of Medicinal Plants from East Africa
por: Simoben, Conrad V., et al.
Publicado: (2020)

Exploring the Binding Interaction of Raf Kinase Inhibitory Protein With the N-Terminal of C-Raf Through Molecular Docking and Molecular Dynamics Simulation
por: Parate, Shraddha, et al.
Publicado: (2021)

Pharmacoinformatics-based investigation of bioactive compounds of Rasam (South Indian recipe) against human cancer
por: Kalimuthu, Arjun Kumar, et al.
Publicado: (2021)

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase
por: Moccia, Marialuisa, et al.
Publicado: (2015)

RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer
por: Mahato, Arun Kumar, et al.
Publicado: (2020)

Ret receptor tyrosine kinase sustains proliferation and tissue maturation in intestinal epithelia
por: Perea, Daniel, et al.
Publicado: (2017)

Binding of EphrinA5 to RET receptor tyrosine kinase: An in vitro study
por: Liu, Yixin, et al.
Publicado: (2018)

Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation
por: Säleby, Joanna, et al.
Publicado: (2019)

RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer
por: Wang, Chunyue, et al.
Publicado: (2022)

Empowering pharmacoinformatics by linked life science data
por: Goldmann, Daria, et al.
Publicado: (2016)

Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.
por: Santoro, M., et al.
Publicado: (1993)

Discovery of Lonafarnib-Like Compounds: Pharmacophore Modeling and Molecular Dynamics Studies
por: Rampogu, Shailima, et al.
Publicado: (2020)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase
por: Cerchia, Laura, et al.
Publicado: (2005)

DNA Topoisomerases Participate in Fragility of the Oncogene RET
por: Dillon, Laura W., et al.
Publicado: (2013)

Alterations of RET, Oncogene in Human Adrenal Tumors
por: Lin, Shiu‐Ru, et al.
Publicado: (1998)

Expression of ret Proto‐oncogene in Human Neuroblastomas
por: Nagao, Minako, et al.
Publicado: (1990)

Roles of the RET Proto-oncogene in Cancer and Development
por: Takahashi, Masahide, et al.
Publicado: (2020)

Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene
por: Mendes Oliveira, Duarte, et al.
Publicado: (2018)

A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions
por: Estrada-Zuniga, Cynthia M., et al.
Publicado: (2022)

Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation In trans
por: Plaza-Menacho, Iván, et al.
Publicado: (2014)

Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018)

Pharmacoinformatics approaches to identify potential hits against tetraacyldisaccharide 4′-kinase (LpxK) of Pseudomonas aeruginosa
por: Damale, Manoj G., et al.
Publicado: (2020)

Retraction: Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase
por: Cerchia, Laura, et al.
Publicado: (2015)

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase
por: Yao, Hang-Ping, et al.
Publicado: (2021)

The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies
por: Cazes, Alex, et al.
Publicado: (2022)

Correction to: Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene
por: Oliveira, Duarte Mendes, et al.
Publicado: (2018)

Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods
por: Kulkarni, Apoorva M., et al.
Publicado: (2022)

Hair graying with aging in mice carrying oncogenic RET
por: Iida, Machiko, et al.
Publicado: (2020)

Distribution of RET proto‐oncogene variants in children with appendicitis
por: Schultz, Jurek, et al.
Publicado: (2022)

Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine
por: Kumarasamy, Vishnu Muthuraj, et al.
Publicado: (2015)

Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection
por: Huang, Qin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jq4qc450247g3bod56ljrki59c